Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3

Newsylist Editorial Desk. (2026, September 28, 2026). Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-09-28/kodiak-s-stock-doubles-as-resurrected-eye-disease-drug-matches-eylea-in-phase-3

@online{newsylist_63822,
  author = {Newsylist Editorial Desk},
  title = {{Kodiak\'s stock doubles as resurrected eye disease drug matches Eylea in phase 3}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-09-28/kodiak-s-stock-doubles-as-resurrected-eye-disease-drug-matches-eylea-in-phase-3},
  note = {Tracked across 2 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3](https://www.newsylist.com/trend/2026-09-28/kodiak-s-stock-doubles-as-resurrected-eye-disease-drug-matches-eylea-in-phase-3)), this event was corroborated across 2 independent sources with a live velocity of 1.